Quick Answer
ARS Pharmaceuticals, Inc. reported Shares Outstanding of 99.29 million shares for fiscal year 2025.
ARS Pharmaceuticals, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 99.29M | +1.4% |
| 2024 | 97.95M | +1.6% |
| 2023 | 96.41M | +2.6% |
| 2022 | 93.94M | +209.3% |
| 2021 | 30.37M | -12.5% |
| 2020 | 34.70M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 98.84M | +1.7% | +0.1% |
| June 30, 2025 | 98.70M | +1.8% | +0.6% |
| March 31, 2025 | 98.13M | +1.6% | +0.2% |
| December 31, 2024 | 97.95M | +1.6% | +0.8% |
| September 30, 2024 | 97.15M | +1.4% | +0.2% |
| June 30, 2024 | 96.94M | +1.7% | +0.4% |
| March 31, 2024 | 96.57M | +2.3% | +0.2% |
| December 31, 2023 | 96.41M | +2.6% | +0.6% |
- ARS Pharmaceuticals, Inc. showed an increase of +1.4% in Shares Outstanding compared to the prior fiscal year.
- Over the 2020–2025 period, ARS Pharmaceuticals, Inc.’s shares outstanding has grown by 186.1% (from 34.70 million shares to 99.29 million shares).
- The most recent figure is from ARS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: